Last reviewed · How we verify
Allogenic Islet Cell Transplantation — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Allogenic Islet Cell Transplantation (Allogenic Islet Cell Transplantation) — Kenneth Brayman, MD.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Allogenic Islet Cell Transplantation TARGET | Allogenic Islet Cell Transplantation | Kenneth Brayman, MD | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Allogenic Islet Cell Transplantation CI watch — RSS
- Allogenic Islet Cell Transplantation CI watch — Atom
- Allogenic Islet Cell Transplantation CI watch — JSON
- Allogenic Islet Cell Transplantation alone — RSS
Cite this brief
Drug Landscape (2026). Allogenic Islet Cell Transplantation — Competitive Intelligence Brief. https://druglandscape.com/ci/allogenic-islet-cell-transplantation. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab